Clinical Trial Update: Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of Quarfloxin in patients with advanced solid tumors or lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Quarfloxin (CX-3543)

Snippet

Sponsor: Cylene Pharmaceuticals | Conditions: Advanced Solid Tumors, Lymphoma | Phase 1 | Status: TERMINATED